Corneal Tissue Engineering: New Applications for Corneal Stromal Stem Cells

The WHO estimates 10 million people in the World are blinded by corneal disease. For many conditions, transplantation of a donor cornea may restore vision. However, there is a global shortage of suitable tissue and a high risk of rejection. The potential of stem cell therapies and tissue engineering approaches to address this significant unmet clinical need was investigated. Limbal epithelial stem cells (LESC) maintain the epithelium, the outermost layer of the cornea, and can be successfully transplanted to restore vision. However, when scarring occurs, transplantation of corneal stroma is required. Human corneal stromal stem cells (CSSC) are involved in stroma maintenance and have previously been shown to restore transparency in cloudy mouse corneas without rejection. This study investigated the development of a surgeon friendly tissue equivalent (TE) for the therapeutic delivery of CSSC and LESCs. For the first time, human corneal rims were rendered transparent for imaging under the iDISCO protocol. CSSC were successfully isolated and characterised with mesenchymal stem cell (MSC) properties confirmed. RAFT-TE, a potential artificial ocular surface, has been extensively investigated by our group using research grade collagen (First Link; not suitable for clinical use). In this thesis, a comparative study was performed to show that Koken collagen (Good Manufacturing Practice compliant) is a suitable replacement for research grade collagen as it did not compromise RAFT-TE properties. Next, co-culture conditions for LESC and CSSC in RAFT-TE were optimised. First, the idea of co-delivering CSSC together with LESCS to the surface of RAFT-TE as a mixed population was trialled. This resulted in unexpected epithelial cell peeling. To overcome this challenge, CSSC were successfully cultured for the first time inside Koken RAFT-TE. CSSC formed cell clusters, remodelled the matrix, and migrated to the surface of the TE. It was also shown that they can be induced to differentiate towards the keratocyte lineage inside the TE. This work highlights the importance of considering clinical manufacturing standards early in the process of development. Overall, it provides valuable insights to develop personalised autologous therapies and off the shelf allogeneic strategies for restoring vision in patients with corneal blindness

Artificial Intelligence and Its Ethical Implications for Marketing

Goncalves, A. R., Pinto, D. C., Rita, P., & Pires, T. (2023). Artificial Intelligence and Its Ethical Implications for Marketing. Emerging Science Journal, 7(2), 313-327. https://doi.org/10.28991/ESJ-2023-07-02-01 --- Funding: This paper received support from the Management of Information Research Center (MagIC), project UIDB/04152/2020, and from the Foundation for Science and Technology (FCT Portugal), project DSAIPA/DS/0113/2019.Despite the recent developments in AI, ethical questions arise when consumers contemplate how their data is being treated. This paper develops a conceptual model building on the theory of acceptance, risk, trust, and attitudes towards AI to understand the drivers that lead consumers to accept AI, considering consumers' ethical concerns. The model was empirically tested with 200 consumers of AI marketing services. The findings reveal that perceived risk significantly impacts attitudes toward AI, ethical concerns, and perceived trust and suggest a significant association between perceived risk, ethical concerns, and social norms. This research provides important theoretical and managerial implications for the ethical aspects of AI in marketing by highlighting the ethical and moral questions surrounding AI's acceptance.publishersversionepub_ahead_of_prin

Hipercolesterolémia Familiar: Em Cada Amostra Sanguínea Uma Oportunidade Diagnóstica

Introdução: A Hipercolesterolémia Familiar (HF) e uma doença hereditária autossómica dominante com uma incidência estimada de 1:500 na sua forma heterozigótica. Caracteriza-se pela existência de níveis de colesterol muito elevados, habitualmente superiores a 300 mg/dl, e que são evidentes desde os primeiros dias de vida. A ausência de um programa de rastreio universal faz do diagnóstico precoce um desafio sobretudo durante a idade pediátrica. O presente trabalho integra-se no Estudo Português de Hipercolesterolémia Familiar e tem como objectivo caracterizar do ponto de vista clinico, laboratorial e genético uma família com HF. Caso clinico: Jovem do sexo masculino de 19 anos seguido em consulta de endocrinologia pediátrica desde os 13 anos por apresentar, em avaliação laboratorial de rotina, colesterol total de 319 mg/ dL. Historia familiar de hipercolesterolemia (colesterol acima de 290 mg/dL) em cinco familiares em primeiro grau, com manifestações clinicas como arco corneano, xantelasmas e ainda morte prematura por enfarte agudo do miocárdio aos 51 anos (avo materna). O estudo genético identificou uma mutação heterozigótica C371X do gene que codifica o receptor LDL (RLDL) no caso index e familiares directos. Trata-se de uma mutação “nonsense” descrita pela primeira vez na população portuguesa e que condiciona uma redução de 50% no número de receptores de LDL (Haploinsuficiência). Conclusão: Nas idades pediátricas, face a ausência de sinais clínicos, a história familiar e o doseamento oportunístico do colesterol sérico, isto e em amostras colhidas por outras razoes, assumem-se como as duas abordagens fundamentais no diagnóstico de HF. As medidas dietéticas e a promoção de estilos de vida saudáveis são as intervenções de primeira linha que devem ser reforçadas perante a confirmação de HF em idade pediátrica. As terapêuticas farmacológicas são ainda tema de discussão na comunidade cientifica, com resultados dispares relativamente a segurança (risco-beneficio) da sua utilização em crianças pre-puberes

Qualidade de vida e sobrecarga dos cuidadores de portadores de Doença Pulmonar Obstrutiva Crônica em oxigenoterapia

OBJECTIVE: to assess the quality of life and burden of caregivers to Chronic Obstructive Pulmonary Disease patients on Long-Term Oxygen Therapy and to investigate the factors influencing this burden. METHOD: this is an analytical, cross-sectional study of 80 persons with Chronic Obstructive Pulmonary Disease on Long-Term Oxygen Therapy who used the specialized outpatient center of the Federal University of São Paulo, and their carers. The following instruments were used: Medical Outcomes Studies 36 (SF-36), Caregiver Burden Scale (CBS) and the Katz Index, along with socio-demographic and clinical variables. RESULTS: the most compromised scores on the carers' quality of life questionnaire were for Vitality and Mental Health. On the Caregiver Burden Scale, the domain which created the greatest burden for carers was the Environment. With the exception of Emotional Involvement, all the domains of quality of life were affected negatively by the domains of caregiver burden. CONCLUSION: it was shown that carers' quality of life was compromised and that they were overburdened with care tasks, confirming that assisting persons with Chronic Obstructive Pulmonary Disease is an important element in carers' quality of life.OBJETIVO: evaluar la calidad de vida y la sobrecarga de cuidados experimentada por cuidadores de portadores de la Enfermedad Pulmonar Obstructiva Crónica en uso de Oxigenoterapia Domiciliar Prolongada e investigar los factores que influencian esa sobrecarga. MÉTODO: se trata de estudio transversal analítico, con 80 portadores de la Enfermedad Pulmonar Obstructiva Crónica en uso de Oxigenoterapia Domiciliar en el ambulatorio especializado de la Universidad Federal de Sao Paulo y de sus respectivos cuidadores, aplicando los instrumentos: Medical Outcomes Studies 36 (SF-36), Caregiver Burden Scale (CBS), índice de Katz y variables sociodemográficas y clínicas. RESULTADOS: los puntajes del cuestionario de calidad de vida de los cuidadores más comprometidos fueron la Vitalidad y la Salud Mental. El Ambiente fue el dominio del Caregiver Burden Scale que generó mayor sobrecarga de cuidados. Con excepción del Envolvimiento Emocional, todos los dominios de calidad de vida fueron influenciados de forma negativa por los dominios de sobrecarga de cuidados. CONCLUSIÓN: se demostró que la calidad de vida y la sobrecarga de cuidados, de los cuidadores, estaban comprometidos, confirmando que cuidar a los portadores de Enfermedad Pulmonar Obstructiva Crónica, es un importante interviniente en la calidad de vida del cuidador.OBJETIVO: avaliar a qualidade de vida e a sobrecarga de cuidados, vivenciada por cuidadores de portadores de Doença Pulmonar Obstrutiva Crônica, em uso de Oxigenoterapia Domiciliar Prolongada, e investigar os fatores que influenciam essa sobrecarga. MÉTODO: trata-se de estudo transversal analítico, com 80 portadores de Doença Pulmonar Obstrutiva Crônica em uso de Oxigenoterapia Domiciliar do ambulatório especializado da Universidade Federal de São Paulo e seus respectivos cuidadores, aplicando-se os instrumentos: Medical Outcomes Studies 36, Caregiver Burden Scale, índice de Katz e variáveis sociodemográficas e clínicas. RESULTADOS: os escores do questionário de qualidade de vida dos cuidadores mais comprometidos foram vitalidade e saúde mental. O ambiente foi o domínio do Caregiver Burden Scale que gerou maior sobrecarga de cuidados. Com exceção do envolvimento emocional, todos os domínios de qualidade de vida foram influenciados de forma negativa pelos domínios de sobrecarga de cuidados. CONCLUSÃO: demonstrou-se comprometimento da qualidade de vida e sobrecarga de cuidados dos cuidadores, confirmando que assistir portadores de Doença Pulmonar Obstrutiva Crônica é um importante interveniente na qualidade de vida do cuidador

FashionCLIP: Connecting Language and Images for Product Representations

The steady rise of online shopping goes hand in hand with the development of increasingly complex ML and NLP models. While most use cases are cast as specialized supervised learning problems, we argue that practitioners would greatly benefit from more transferable representations of products. In this work, we build on recent developments in contrastive learning to train FashionCLIP, a CLIP-like model for the fashion industry. We showcase its capabilities for retrieval, classification and grounding, and release our model and code to the community.Comment: Code will soon be available at https://github.com/patrickjohncyh, dataset at https://github.com/Farfetc

Genetic variants of ABC and SLC transporter genes and chronic myeloid leukaemia: impact on susceptibility and prognosis

Solute carrier (SLC) and ATP-binding cassette (ABC) transporters comprise a variety of proteins expressed on cell membranes responsible for intrusion or extrusion of substrates, respectively, including nutrients, xenobiotics, and chemotherapeutic agents. These transporters mediate the cellular disposition of tyrosine kinase inhibitors (TKIs), and their genetic variants could affect its function, potentially predisposing patients to chronic myeloid leukaemia (CML) and modulating treatment response. We explored the impact of genetic variability (single nucleotide variants—SNVs) of drug transporter genes (ABCB1, ABCG2, SLC22A1, and SLC22A5) on CML susceptibility, drug response, and BCR-ABL1 mutation status. We genotyped 10 SNVs by tetra-primers-AMRS-PCR in 198 CML patients and 404 controls, and assessed their role in CML susceptibility and prognosis. We identified five SNVs associated with CML predisposition, with some variants increasing disease risk, including TT genotype ABCB1 (rs1045642), and others showing a protective effect (GG genotype SLC22A5 rs274558). We also observed different haplotypes and genotypic profiles associated with CML predisposition. Relating to drug response impact, we found that CML patients with the CC genotype (rs2231142 ABCG2) had an increased risk of TKI resistance (six-fold). Additionally, CML patients carrying the CG genotype (rs683369 SLC22A1) presented a 4.54-fold higher risk of BCR-ABL1 mutations. Our results suggest that drug transporters’ SNVs might be involved in CML susceptibility and TKI response, and predict the risk of BCR-ABL1 mutations, highlighting the impact that SNVs could have in therapeutic selection.info:eu-repo/semantics/publishedVersio

Metabolic Footprint, towards Understanding Type 2 Diabetes beyond Glycemia

Type 2 diabetes (T2D) heterogeneity is a major determinant of complications risk and treatment response. Using cluster analysis, we aimed to stratify glycemia within metabolic multidimensionality and extract pathophysiological insights out of metabolic profiling. We performed a cluster analysis to stratify 974 subjects (PREVADIAB2 cohort) with normoglycemia, prediabetes, or non-treated diabetes. The algorithm was informed by age, anthropometry, and metabolic milieu (glucose, insulin, C-peptide, and free fatty acid (FFA) levels during the oral glucose tolerance test OGTT). For cluster profiling, we additionally used indexes of metabolism mechanisms (e.g., tissue-specific insulin resistance, insulin clearance, and insulin secretion), non-alcoholic fatty liver disease (NAFLD), and glomerular filtration rate (GFR). We found prominent heterogeneity within two optimal clusters, mainly representing normometabolism (Cluster-I) or insulin resistance and NAFLD (Cluster-II), at higher granularity. This was illustrated by sub-clusters showing similar NAFLD prevalence but differentiated by glycemia, FFA, and GFR (Cluster-II). Sub-clusters with similar glycemia and FFA showed dissimilar insulin clearance and secretion (Cluster-I). This work reveals that T2D heterogeneity can be captured by a thorough metabolic milieu and mechanisms profiling-metabolic footprint. It is expected that deeper phenotyping and increased pathophysiology knowledge will allow to identify subject's multidimensional profile, predict their progression, and treat them towards precision medicine.publishersversionpublishe

SARS-CoV-2 N501Y Introductions and Transmissions in Switzerland from Beginning of October 2020 to February 2021—Implementation of Swiss-Wide Diagnostic Screening and Whole Genome Sequencing

The rapid spread of the SARS-CoV-2 lineages B.1.1.7 (N501Y.V1) throughout the UK, B.1.351 (N501Y.V2) in South Africa, and P.1 (B.1.1.28.1; N501Y.V3) in Brazil has led to the definition of variants of concern (VoCs) and recommendations for lineage specific surveillance. In Switzerland, during the last weeks of December 2020, we established a nationwide screening protocol across multiple laboratories, focusing first on epidemiological and microbiological definitions. In January 2021, we validated and implemented an N501Y-specific PCR to rapidly screen for VoCs, which are then confirmed using amplicon sequencing or whole genome sequencing (WGS). A total of 13,387 VoCs have been identified since the detection of the first Swiss case in October 2020, with 4194 being B.1.1.7, 172 B.1.351, and 7 P.1. The remaining 9014 cases of VoCs have been described without further lineage specification. Overall, all diagnostic centers reported a rapid increase of the percentage of detected VOCs, with a range of 6 to 46% between 25 to 31 of January 2021 increasing towards 41 to 82% between 22 to 28 of February. A total of 739 N501Y positive genomes were analysed and show a broad range of introduction events to Switzerland. In this paper, we describe the nationwide coordination and implementation process across laboratories, public health institutions, and researchers, the first results of our N501Y-specific variant screening, and the phylogenetic analysis of all available WGS data in Switzerland, that together identified the early introduction events and subsequent community spreading of the VoCs

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.

BACKGROUND: The replication-competent recombinant vesicular stomatitis virus (rVSV)-based vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety and immunogenicity testing before its use in West Africa. METHODS: We performed three open-label, dose-escalation phase 1 trials and one randomized, double-blind, controlled phase 1 trial to assess the safety, side-effect profile, and immunogenicity of rVSV-ZEBOV at various doses in 158 healthy adults in Europe and Africa. All participants were injected with doses of vaccine ranging from 300,000 to 50 million plaque-forming units (PFU) or placebo. RESULTS: No serious vaccine-related adverse events were reported. Mild-to-moderate early-onset reactogenicity was frequent but transient (median, 1 day). Fever was observed in up to 30% of vaccinees. Vaccine viremia was detected within 3 days in 123 of the 130 participants (95%) receiving 3 million PFU or more; rVSV was not detected in saliva or urine. In the second week after injection, arthritis affecting one to four joints developed in 11 of 51 participants (22%) in Geneva, with pain lasting a median of 8 days (interquartile range, 4 to 87); 2 self-limited cases occurred in 60 participants (3%) in Hamburg, Germany, and Kilifi, Kenya. The virus was identified in one synovial-fluid aspirate and in skin vesicles of 2 other vaccinees, showing peripheral viral replication in the second week after immunization. ZEBOV-glycoprotein-specific antibody responses were detected in all the participants, with similar glycoprotein-binding antibody titers but significantly higher neutralizing antibody titers at higher doses. Glycoprotein-binding antibody titers were sustained through 180 days in all participants. CONCLUSIONS: In these studies, rVSV-ZEBOV was reactogenic but immunogenic after a single dose and warrants further evaluation for safety and efficacy. (Funded by the Wellcome Trust and others; ClinicalTrials.gov numbers, NCT02283099, NCT02287480, and NCT02296983; Pan African Clinical Trials Registry number, PACTR201411000919191.)